Brokerages Set Quince Therapeutics, Inc. (NASDAQ:QNCX) PT at $8.00

Quince Therapeutics, Inc. (NASDAQ:QNCX) has earned a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $8.00.

Several brokerages have recently issued reports on QNCX. Weiss Ratings reissued a “sell (e+)” rating on shares of Quince Therapeutics in a research report on Monday, December 15th. D. Boral Capital upped their target price on shares of Quince Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Finally, Zacks Research raised Quince Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th.

Institutional Investors Weigh In On Quince Therapeutics

Several institutional investors have recently bought and sold shares of QNCX. Nantahala Capital Management LLC grew its stake in shares of Quince Therapeutics by 21.6% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,073,729 shares of the company’s stock worth $5,010,000 after acquiring an additional 545,427 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Quince Therapeutics by 21.3% in the third quarter. Vanguard Group Inc. now owns 1,763,387 shares of the company’s stock worth $2,874,000 after purchasing an additional 309,349 shares in the last quarter. Millennium Management LLC boosted its holdings in Quince Therapeutics by 1,152.9% during the third quarter. Millennium Management LLC now owns 1,386,776 shares of the company’s stock worth $2,260,000 after purchasing an additional 1,276,094 shares during the last quarter. Ieq Capital LLC bought a new position in Quince Therapeutics in the first quarter valued at $1,073,000. Finally, ADAR1 Capital Management LLC grew its position in Quince Therapeutics by 442.1% in the third quarter. ADAR1 Capital Management LLC now owns 775,034 shares of the company’s stock valued at $1,263,000 after purchasing an additional 632,076 shares in the last quarter. Institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Price Performance

NASDAQ:QNCX opened at $3.65 on Thursday. The business’s 50-day simple moving average is $2.54 and its 200-day simple moving average is $1.95. Quince Therapeutics has a fifty-two week low of $0.72 and a fifty-two week high of $4.55. The stock has a market capitalization of $203.23 million, a PE ratio of -3.02 and a beta of 1.02.

Quince Therapeutics (NASDAQ:QNCX) last posted its earnings results on Wednesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). On average, research analysts expect that Quince Therapeutics will post -1.21 earnings per share for the current year.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.